[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 35 of about 35
1. Sinha S, Sinha N, Bandyopadhyay R, Mondal SK: Robinson's cytological grading on aspirates of breast carcinoma: Correlation with Bloom Richardson's histological grading. J Cytol; 2009 Oct;26(4):140-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robinson's cytological grading on aspirates of breast carcinoma: Correlation with Bloom Richardson's histological grading.
  • BACKGROUND: Cytological grading (CG) on aspirates of breast carcinoma is a useful tool for surgical maneuver and prognosis.
  • AIMS: An endeavor was made to use CG on aspirates of breast carcinoma using Robinson's grade and to correlate it with Bloom Richardsons' histopathological grading.
  • MATERIALS AND METHODS: A total of 59 patients of breast carcinoma, aged 28-57 years, were aspirated and the smears were graded using Robinson's criteria.
  • For grade I and II tumors, there was substantial strength of agreement between cytology and histopathology, while in grade III, the concordance was nearly perfect.
  • Lymph node metastasis was observed in three with cytological grade II, 28 of grade III and none of grade I.
  • All grade I had stage A, two of grade II had stage B, while all grade III had either stage B or stage C disease.
  • CONCLUSIONS: Thus, CG of breast carcinoma correlates well with histopathological grading and may well be useful as a prognostic marker.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Anal Quant Cytol Histol. 1987 Dec;9(6):480-4 [2829937.001]
  • [Cites] Lancet. 1994 Apr 16;343(8903):947-9 [7909010.001]
  • [Cites] Diagn Cytopathol. 1997 Apr;16(4):295-311 [9143822.001]
  • [Cites] Cancer. 1997 Feb 25;81(1):16-21 [9100536.001]
  • [Cites] Diagn Cytopathol. 1995 Oct;13(3):260-5 [8575287.001]
  • [Cites] Diagn Cytopathol. 1995 Dec;13(5):388-95 [8834313.001]
  • [Cites] Diagn Cytopathol. 1996 Aug;15(2):116-20 [8872432.001]
  • [Cites] Diagn Cytopathol. 1994;10(3):203-8 [8050325.001]
  • (PMID = 21938177.001).
  • [ISSN] 0974-5165
  • [Journal-full-title] Journal of cytology
  • [ISO-abbreviation] J Cytol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3167998
  • [Keywords] NOTNLM ; Bloom Richardson's grading / Breast carcinoma / Robinson's grading / fine needle aspiration cytology
  •  go-up   go-down


2. Rubio CA, Nilsson PJ: Squamous-cell carcinoma of the anus with high intratumoral lymphocytosis and its clinical implications. Anticancer Res; 2008 Jul-Aug;28(4C):2469-72
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous-cell carcinoma of the anus with high intratumoral lymphocytosis and its clinical implications.
  • BACKGROUND: It has been claimed that patients with squamous cell carcinoma of the anal canal (SCCAC) showing intraepithelial lymphocytes have a poor prognosis.
  • All these 8 patients with SCCAC/HTIL had clinical stage II and III while these stages comprised 83% of the remaining SCCAC cases.
  • CONCLUSION: Despite the 8 SCCAC/HTIL patients having a more advanced clinical stage than the remaining 269 SCCAC patients, these 8 patients had longer survival.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Lymphocytes, Tumor-Infiltrating / pathology. Lymphocytosis / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18751436.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


3. Pawlik TM, Hawke DH, Liu Y, Krishnamurthy S, Fritsche H, Hunt KK, Kuerer HM: Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein. BMC Cancer; 2006;6:68
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein.
  • We sought to determine whether ICAT technology could quantify and identify differential expression of tumor-specific proteins in nipple aspirate fluid (NAF) from the tumor-bearing and contralateral disease-free breasts of patients with unilateral early-stage breast cancer.
  • METHODS: Paired NAF samples from 18 women with stage I or II unilateral invasive breast carcinoma and 4 healthy volunteers were analyzed using ICAT labeling, sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE), liquid chromatography, and MS.
  • Western blot analysis of NAF from an independent sample set from 12 women (8 with early-stage breast cancer and 4 healthy volunteers) was also performed.
  • Western blot analysis of pooled samples of NAF from healthy volunteers versus NAF from women with breast cancer confirmed the overexpression of vitamin D-binding protein in tumor-bearing breasts.
  • Proteomic screening techniques using ICAT and NAF may be used to find markers for diagnosis of breast cancer.
  • [MeSH-minor] Blotting, Western. Body Fluids / metabolism. Carbon Isotopes. Carcinoma / diagnosis. Carcinoma / metabolism. Chromatography, Liquid. Female. Humans. Middle Aged. Peptides / analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proteomics. 2003 Oct;3(10):1863-73 [14625848.001]
  • [Cites] Mol Cell Proteomics. 2003 Nov;2(11):1198-204 [14506205.001]
  • [Cites] Bioconjug Chem. 2004 Mar-Apr;15(2):380-8 [15025535.001]
  • [Cites] J Biol Chem. 2004 Apr 2;279(14):14129-39 [14729674.001]
  • [Cites] J Biol Chem. 2004 May 7;279(19):20127-36 [14988394.001]
  • [Cites] Biochem Soc Trans. 2004 Jun;32(Pt3):520-3 [15157176.001]
  • [Cites] J Proteome Res. 2004 May-Jun;3(3):604-12 [15253443.001]
  • [Cites] Genome Biol. 2004;5(8):R54 [15287976.001]
  • [Cites] World J Gastroenterol. 2004 Sep 15;10(18):2652-6 [15309713.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6402-9 [15374947.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Oct;130(10):615-22 [15243804.001]
  • [Cites] Mol Cell Proteomics. 2004 Oct;3(10):960-9 [15238602.001]
  • [Cites] J Natl Cancer Inst. 1977 Oct;59(4):1073-80 [903989.001]
  • [Cites] Lancet. 1979 Dec 22-29;2(8156-8157):1335-6 [92676.001]
  • [Cites] Cancer Res. 1980 Dec;40(12):4764-7 [6254651.001]
  • [Cites] Biochem Biophys Res Commun. 1981 Aug 31;101(4):1131-8 [6272774.001]
  • [Cites] Cancer Res. 1981 Dec;41(12 Pt 1):5121-4 [6272989.001]
  • [Cites] Cancer Res. 1984 Apr;44(4):1677-81 [6322984.001]
  • [Cites] Nat Biotechnol. 1999 Jul;17(7):676-82 [10404161.001]
  • [Cites] Nat Biotechnol. 1999 Oct;17(10):994-9 [10504701.001]
  • [Cites] FEBS J. 2005 Jan;272(1):2-15 [15634327.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Feb 5;815(1-2):215-25 [15652811.001]
  • [Cites] Breast Cancer Res Treat. 2005 Jan;89(2):149-57 [15692757.001]
  • [Cites] Int J Cancer. 2005 May 1;114(5):791-6 [15609313.001]
  • [Cites] Mol Biotechnol. 2005 Mar;29(3):233-44 [15767701.001]
  • [Cites] Proteomics. 2005 May;5(7):1797-805 [15825149.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):349-55 [12590263.001]
  • [Cites] N Engl J Med. 1992 Jul 30;327(5):319-28 [1620171.001]
  • [Cites] Breast Cancer Res Treat. 1994;31(2-3):357-70 [7881112.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Dec;5(12):967-70 [8959318.001]
  • [Cites] Anal Chem. 1997 Apr 15;69(8):1518-24 [9109352.001]
  • [Cites] Br J Cancer. 1997;76(4):494-501 [9275027.001]
  • [Cites] N Engl J Med. 1998 Apr 16;338(16):1089-96 [9545356.001]
  • [Cites] Lancet. 2000 Aug 12;356(9229):567 [10950239.001]
  • [Cites] Curr Opin Biotechnol. 2000 Aug;11(4):413-8 [10975463.001]
  • [Cites] Curr Opin Chem Biol. 2000 Oct;4(5):489-94 [11006534.001]
  • [Cites] Ann N Y Acad Sci. 2000;923:312-5 [11193768.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1462-7 [11230492.001]
  • [Cites] Breast Cancer Res. 2000;2(2):92-9 [11250698.001]
  • [Cites] Anal Chem. 2001 Mar 1;73(5):978-86 [11289445.001]
  • [Cites] EMBO J. 2001 Sep 3;20(17):4782-93 [11532942.001]
  • [Cites] Nat Biotechnol. 2001 Oct;19(10):946-51 [11581660.001]
  • [Cites] J Am Soc Mass Spectrom. 2001 Dec;12(12):1238-46 [11766750.001]
  • [Cites] Dis Markers. 2001;17(4):301-7 [11790897.001]
  • [Cites] J Mass Spectrom. 2002 Jan;37(1):1-14 [11813306.001]
  • [Cites] Breast J. 2001 Nov-Dec;7(6):378-87 [11843848.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Nat Biotechnol. 2002 May;20(5):512-5 [11981568.001]
  • [Cites] Biochemistry. 2002 May 28;41(21):6714-22 [12022875.001]
  • [Cites] EMBO J. 2002 Oct 1;21(19):5088-96 [12356725.001]
  • [Cites] Curr Opin Chem Biol. 2002 Oct;6(5):666-75 [12413552.001]
  • [Cites] Cancer. 2002 Dec 1;95(11):2276-82 [12436432.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6740-9 [12438275.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):749-54 [12576445.001]
  • [Cites] Anal Chem. 2003 May 1;75(9):2159-65 [12720356.001]
  • [Cites] Breast Cancer Res. 2003;5(4):R82-7 [12817998.001]
  • [Cites] J Am Soc Mass Spectrom. 2003 Jul;14(7):696-703 [12837591.001]
  • [Cites] Breast Cancer Res. 2003;5(6):320-8 [14580250.001]
  • [Cites] Int J Biol Markers. 2003 Oct-Dec;18(4):241-72 [14756541.001]
  • (PMID = 16542425.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carbon Isotopes; 0 / Peptides; 0 / Vitamin D-Binding Protein
  • [Other-IDs] NLM/ PMC1431555
  •  go-up   go-down


Advertisement
4. Tournier-Rangeard L, Peiffert D, Lafond C, Mege A, Metayer Y, Marchesi V, Buchheit I, Uwer L, Conroy T, Kaminsky MC: [Long-term results and prognostic factors of squamous cell carcinoma of the anal canal treated by irradiation]. Cancer Radiother; 2007 Jun;11(4):169-77
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term results and prognostic factors of squamous cell carcinoma of the anal canal treated by irradiation].
  • [Transliterated title] Résultats à long terme et facteurs pronostiques des carcinomes épidermoïdes du canal anal traités par irradiation.
  • PURPOSE: To analyze the prognostic factors of loco regional control (LRC), specific survival (SS) and sphincter conservation (SC) of patients treated by curative and conservative irradiation for an epidermoid cancer of anal canal in our institution.
  • Forty-three pts were stage I, 154 stage II, 31 stage IIIA and 53 stage IIIB.
  • Five-years-LRC were 71.5% (88% for stage I, 69% for stage II, 77%, for stage IIIA and 60% for stage IIIB).
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17400501.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


5. Shah SA, Spinale FG, Ikonomidis JS, Stroud RE, Chang EI, Reed CE: Differential matrix metalloproteinase levels in adenocarcinoma and squamous cell carcinoma of the lung. J Thorac Cardiovasc Surg; 2010 Apr;139(4):984-90; discussion 990
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential matrix metalloproteinase levels in adenocarcinoma and squamous cell carcinoma of the lung.
  • OBJECTIVE: The matrix metalloproteinases (MMPs) have been implicated in the aggressive course of non-small cell lung cancer (NSCLC).
  • METHODS: NSCLC samples and remote normal samples were obtained from patients with stage I or II NSCLC with either squamous cell (n = 22) or adenocarcinoma (n = 19) histologic characteristics.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
  • [Cites] Cancer Metastasis Rev. 2006 Mar;25(1):45-56 [16680571.001]
  • [Cites] Br J Cancer. 2006 Apr 10;94(7):941-6 [16538215.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5448-53 [17000679.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2054-60 [17404086.001]
  • [Cites] Semin Cell Dev Biol. 2008 Feb;19(1):52-60 [17625931.001]
  • [Cites] Int J Biochem Cell Biol. 2008;40(6-7):1362-78 [18258475.001]
  • [Cites] Cancer Sci. 2008 Jun;99(6):1188-94 [18422740.001]
  • [Cites] Cancer Sci. 2008 Nov;99(11):2185-92 [18823373.001]
  • [Cites] Ann Thorac Surg. 2008 Nov;86(5):1576-83 [19049753.001]
  • [Cites] Anticancer Res. 2009 Jan;29(1):67-74 [19331134.001]
  • [Cites] Int J Cancer. 2009 Aug 15;125(4):894-901 [19480010.001]
  • [Cites] Anticancer Res. 2009 Jul;29(7):2513-7 [19596921.001]
  • [Cites] J Pathol. 2000 Feb;190(2):150-6 [10657012.001]
  • [Cites] Circulation. 2000 Oct 17;102(16):1944-9 [11034943.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3944-8 [11051242.001]
  • [Cites] Oncol Rep. 2001 Mar-Apr;8(2):421-4 [11182067.001]
  • [Cites] Science. 2002 Mar 29;295(5564):2387-92 [11923519.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] J Cell Sci. 2002 Oct 1;115(Pt 19):3719-27 [12235282.001]
  • [Cites] Int J Cancer. 2003 Feb 20;103(5):647-51 [12494473.001]
  • [Cites] Circ Res. 2003 May 2;92(8):827-39 [12730128.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):745-51 [12866035.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):3098-104 [12912961.001]
  • [Cites] Int J Cancer. 2003 Nov 20;107(4):541-50 [14520690.001]
  • [Cites] Lung Cancer. 2004 Aug;45(2):171-9 [15246188.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3218-29 [15249585.001]
  • [Cites] Pathol Int. 1997 Jul;47(7):461-9 [9234385.001]
  • [Cites] Clin Cancer Res. 1999 Jan;5(1):149-53 [9918213.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):842-9 [15681529.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1086-92 [15709175.001]
  • [Cites] Circulation. 2005 Mar 8;111(9):1166-74 [15723986.001]
  • [Cites] Int J Colorectal Dis. 2005 May;20(3):245-52 [15592677.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1676-84 [15754326.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2831-9 [15837997.001]
  • [Cites] Anal Biochem. 2005 Aug 1;343(1):54-65 [15953581.001]
  • [Cites] Am J Cardiol. 2006 Feb 15;97(4):532-7 [16461051.001]
  • [Cites] Lung Cancer. 2006 Mar;51(3):313-21 [16423426.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):227-39 [16498445.001]
  • [Cites] Circulation. 2006 Jul 4;114(1 Suppl):I365-70 [16820601.001]
  • (PMID = 20304142.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL059165; United States / NHLBI NIH HHS / HL / R01 HL059165-11; United States / NHLBI NIH HHS / HL / HL59165; United States / NHLBI NIH HHS / HL / HL81691
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.24.- / Matrix Metalloproteinases
  • [Other-IDs] NLM/ NIHMS167053; NLM/ PMC2844342
  •  go-up   go-down


6. Attia S, Traynor AM, Kim K, Merchant JJ, Hoang T, Ahuja HG, Beatty PA, Hansen RM, Masters GA, Oettel KR, Shapiro GR, Larson MM, Larson ML, Schiller JH: Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study. J Thorac Oncol; 2008 Sep;3(9):1018-25
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study.
  • INTRODUCTION: Exisulind is an apoptotic agent with preclinical activity in non-small cell lung cancer (NSCLC).
  • METHODS: Chemotherapy-naive patients >/=70-years-old with stage IIIB-IV NSCLC and a performance status (PS) </=2 were eligible.
  • Primary endpoints were the maximum tolerated dose (phase I) and time-to-progression (phase II) of oral exisulind with 25 mg/m/wk of intravenous vinorelbine on a 28-day cycle.
  • Thirty phase II patients (median PS 1; median age 78 years) were enrolled.
  • Phase II median time-to-progression was 4.7 months (95% CI: 3.1-9.3 months) and median OS was 9.6 months (95% CI: 6.6-19.1 months).

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6178-84 [10626810.001]
  • [Cites] Oncologist. 2007 Dec;12(12):1416-24 [18165618.001]
  • [Cites] Cancer. 2000 Jun 15;88(12):2677-85 [10870049.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3338-42 [10910034.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2690-5 [10914711.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4136-41 [11051267.001]
  • [Cites] Oncologist. 2001;6 Suppl 1:4-7 [11181997.001]
  • [Cites] J Clin Oncol. 2002 Jan 15;20(2):494-502 [11786579.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):904-12 [11895925.001]
  • [Cites] Mol Cancer Ther. 2003 May;2(5):479-88 [12748310.001]
  • [Cites] Eur J Cancer. 2003 Nov;39(16):2264-72 [14556916.001]
  • [Cites] J Am Geriatr Soc. 1968 May;16(5):622-6 [5646906.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Clin Pharmacol Ther. 1985 Aug;38(2):228-34 [4017423.001]
  • [Cites] Clin Pharmacol Ther. 1985 Oct;38(4):387-93 [4042521.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] J Pharm Biomed Anal. 1995 Dec;14(1-2):213-20 [8833984.001]
  • [Cites] Eur J Cancer. 1997 Feb;33(2):301-3 [9135505.001]
  • [Cites] Eur J Cancer. 1997 Mar;33(3):392-7 [9155522.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2452-9 [9192825.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1250-9 [9849488.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2831-9 [15837997.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):3125-37 [15860872.001]
  • [Cites] Clin Lung Cancer. 2005 May;6(6):361-6 [15943897.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5892-9 [16043829.001]
  • [Cites] Cancer. 2005 Nov 1;104(9):1998-2005 [16206252.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3187-205 [16682719.001]
  • [Cites] Eur J Cancer. 2006 Oct;42(15):2433-53 [16750358.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cancer Control. 2007 Jan;14(1):32-43 [17242669.001]
  • [Cites] J Thorac Oncol. 2006 Mar;1(3):218-25 [17409860.001]
  • [Cites] J Thorac Oncol. 2006 Sep;1(7):673-8 [17409935.001]
  • [Cites] J Clin Oncol. 2007 May 10;25(14):1824-31 [17488980.001]
  • [Cites] J Thorac Oncol. 2007 Oct;2(10):933-8 [17909356.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5381-9 [18048819.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):78-89 [10656435.001]
  • (PMID = 18758305.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA014520-33; United States / NCI NIH HHS / CA / T32 CA009614-18; United States / NCI NIH HHS / CA / CA062491-14; United States / NCI NIH HHS / CA / CA014520-34S2; United States / NCI NIH HHS / CA / T32 CA009614-14; United States / NCI NIH HHS / CA / T32 CA009614-11; United States / NCI NIH HHS / CA / T32 CA009614-10; United States / NCI NIH HHS / CA / CA009614-15; United States / NCI NIH HHS / CA / T32 CA009614-15; United States / NCI NIH HHS / CA / CA087718-08; United States / NCI NIH HHS / CA / CA009614-16A1; United States / NCI NIH HHS / CA / CA014520-31S1; United States / NCI NIH HHS / CA / P30 CA014520-33S1; United States / NCI NIH HHS / CA / P30 CA014520-32; None / None / / P30 CA014520-33; United States / NCI NIH HHS / CA / T32 CA009614-16A1; United States / NCI NIH HHS / CA / P30 CA014520-32S1; United States / NCI NIH HHS / CA / K12 CA087718-07; United States / NCI NIH HHS / CA / P30 CA014520-34; United States / NCI NIH HHS / CA / U01 CA062491-11; United States / NCI NIH HHS / CA / P30 CA014520; None / None / / P30 CA014520-32; United States / NCI NIH HHS / CA / CA014520-34S1; United States / NCI NIH HHS / CA / U01 CA062491-10; United States / NCI NIH HHS / CA / CA062491-11; United States / NCI NIH HHS / CA / CA062491-13; United States / NCI NIH HHS / CA / P30 CA014520-33S2; United States / NCI NIH HHS / CA / CA009614-14; United States / NCI NIH HHS / CA / P30 CA014520-31; United States / NCI NIH HHS / CA / U01 CA062491; United States / NCI NIH HHS / CA / K12 CA087718; United States / NCI NIH HHS / CA / CA009614-12; None / None / / P30 CA014520-30; United States / NCI NIH HHS / CA / CA014520-33S2; United States / NCI NIH HHS / CA / U01 CA062491-13; United States / NCI NIH HHS / CA / CA009614-17; United States / NCI NIH HHS / CA / P30 CA014520-31S1; United States / NCI NIH HHS / CA / CA014520-32S1; United States / NCI NIH HHS / CA / P30 CA14520; United States / NCI NIH HHS / CA / T32 CA009614; United States / NCI NIH HHS / CA / CA009614-11; None / None / / P30 CA014520-34; United States / NCI NIH HHS / CA / P30 CA014520-30; United States / NCI NIH HHS / CA / T32 CA009614-13; None / None / / P30 CA014520-31; United States / NCI NIH HHS / CA / CA009614-18; United States / NCI NIH HHS / CA / CA062491-12; United States / NCI NIH HHS / CA / P30 CA014520-34S1; United States / NCI NIH HHS / CA / CA009614-13; United States / NCI NIH HHS / CA / T32 CA009614-17; United States / NCI NIH HHS / CA / U01 CA062491-12; United States / NCI NIH HHS / CA / T32 CA009614-12; United States / NCI NIH HHS / CA / U01 CA062491-14; United States / NCI NIH HHS / CA / P30 CA014520-34S2; United States / NCI NIH HHS / CA / K12 CA087718-08; United States / NCI NIH HHS / CA / CA009614-10; United States / NCI NIH HHS / CA / CA014520-33S1
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 184SNS8VUH / Sulindac; 5V9KLZ54CY / Vinblastine; K619IIG2R9 / sulindac sulfone; Q6C979R91Y / vinorelbine
  • [Other-IDs] NLM/ NIHMS52764; NLM/ PMC2562273
  •  go-up   go-down


7. El Badry AA, El-Fadle AA, El-Balshy AL: Tissue inhibitor of matrix metalloproteinase-2 in nasopharyngeal carcinoma. MedGenMed; 2007;9(3):3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue inhibitor of matrix metalloproteinase-2 in nasopharyngeal carcinoma.
  • The present study was designed to clarify the role of TIMP-2 in nasopharyngeal carcinoma (NPC) patients and to evaluate its importance relative to clinicopathologic parameters.
  • Clinically, in accordance with TNM classification (T: tumor size, N: lymph node involvement, M: distant metastasis), 8 cases were diagnosed as stage II, 12 as stage III, and 10 cases as stage IV; however, pathologic typing with use of the World Health Organization (WHO) classification revealed the presence of 9 specimens of squamous cell carcinoma (WHO type 1), 6 cases of nonkeratinizing carcinoma (WHO type 2), and 15 cases of undifferentiated carcinoma (WHO type 3).
  • In addition, there was a significant positive correlation between TIMP-2 protein positivity and either the clinical staging or the histopathologic typing (P < .01) using Chi-square test (x(2)), suggesting that TIMP-2 can be used as a marker of the severity of NPC.Accordingly, we can assume that TIMP-2 may play a role in regional lymph node and/or distant metastasis and in progression of squamous cell carcinoma.
  • [MeSH-major] Carcinoma / chemistry. Carcinoma / enzymology. Nasopharyngeal Neoplasms / chemistry. Nasopharyngeal Neoplasms / enzymology. Tissue Inhibitor of Metalloproteinase-2 / analysis

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1999 Nov;189(3):300-8 [10547590.001]
  • [Cites] Am J Clin Pathol. 1993 Jan;99(1):18-23 [8422010.001]
  • [Cites] Adv Exp Med Biol. 2000;465:469-83 [10810650.001]
  • [Cites] Br J Cancer. 2000 Jul;83(2):215-8 [10901373.001]
  • [Cites] Hum Pathol. 2000 Aug;31(8):895-904 [10987249.001]
  • [Cites] Int J Oncol. 2000 Dec;17(6):1099-105 [11078794.001]
  • [Cites] Int J Cancer. 2001 Jan 20;95(1):44-50 [11241310.001]
  • [Cites] J Med Invest. 2001 Feb;48(1-2):31-43 [11286015.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):813-20 [11448356.001]
  • [Cites] Int J Colorectal Dis. 2001 Jun;16(3):133-40 [11459286.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3113-9 [11595703.001]
  • [Cites] Mod Pathol. 2002 Jan;15(1):26-34 [11796838.001]
  • [Cites] Isr Med Assoc J. 2002 Apr;4(4):247-51 [12001695.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 28;99(11):7414-9 [12032297.001]
  • [Cites] Ai Zheng. 2002 Jan;21(1):91-4 [12500407.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Otolaryngol Head Neck Surg. 1983 Jun;91(3):255-62 [6308537.001]
  • [Cites] J Biol Chem. 1989 Oct 15;264(29):17374-8 [2793861.001]
  • [Cites] Int J Cancer. 1994 Nov 1;59(3):339-44 [7927938.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):5331-8 [7890645.001]
  • [Cites] Cancer Res. 1996 Apr 1;56(7):1654-9 [8603416.001]
  • [Cites] FEBS Lett. 1996 May 6;385(3):238-40 [8647259.001]
  • [Cites] Cancer Res. 1996 Jun 15;56(12):2707-10 [8665498.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):139-44 [8988738.001]
  • [Cites] Eur J Cell Biol. 1997 Oct;74(2):111-22 [9352216.001]
  • [Cites] Nat Genet. 1997 Dec;17(4):439-44 [9398846.001]
  • [Cites] Br J Cancer. 1998 Feb;77(4):650-5 [9484825.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1359-66 [9529029.001]
  • [Cites] Clin Cancer Res. 1997 Sep;3(9):1623-8 [9815852.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):467-73 [9927064.001]
  • [Cites] Anticancer Res. 1999 Mar-Apr;19(2C):1589-92 [10365151.001]
  • [Cites] J Biol Chem. 1999 Jul 30;274(31):21491-4 [10419448.001]
  • [Cites] Head Neck. 1999 Oct;21(7):627-38 [10487950.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16485-90 [1653238.001]
  • [Cites] Anticancer Res. 2000 Mar-Apr;20(2B):1085-91 [10810401.001]
  • (PMID = 18092010.001).
  • [ISSN] 1531-0132
  • [Journal-full-title] MedGenMed : Medscape general medicine
  • [ISO-abbreviation] MedGenMed
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2
  • [Other-IDs] NLM/ PMC2100075
  •  go-up   go-down


8. Takashima A, Shimada Y, Hamaguchi T, Ito Y, Masaki T, Yamaguchi S, Kondo Y, Saito N, Kato T, Ohue M, Higashino M, Moriya Y, Colorectal Cancer Study Group of the Japan Clinical Oncology Group: Current therapeutic strategies for anal squamous cell carcinoma in Japan. Int J Clin Oncol; 2009 Oct;14(5):416-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current therapeutic strategies for anal squamous cell carcinoma in Japan.
  • BACKGROUND: In Western countries, chemoradiotherapy (CRT) is well established as the standard therapy for stages II/III anal squamous cell carcinoma (ASCC).
  • The Colorectal Cancer Study Group of the Japan Clinical Oncology Group (JCOG-CCSG) conducted a survey to determine the current therapeutic strategies for ASCC in Japan.
  • The target subjects were patients with stages II/III ASCC, diagnosed from January 2000 to December 2004, who were 20-80 years of age with normal major organ function and no severe complications.
  • Detailed information was obtained for 55 subjects; 25 (45%) had stage II ASCC and 30 (55%) had stage III ASCC.
  • [MeSH-major] Anus Neoplasms / therapy. Asian Continental Ancestry Group. Carcinoma, Squamous Cell / therapy. Digestive System Surgical Procedures

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19856049.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Japan
  • [Investigator] Kondo Y; Ohtsuka K; Shiiba K; Sato T; Yoshimi F; Kotake K; Sawada T; Mochizuki H; Konishi F; Saito N; Moriya Y; Masaki T; Aoki T; Takahashi K; Hasegawa H; Kenichi S; Sumiyama Y; Sato T; Akaike M; Kudo S; Yamada T; Munakata Y; Shigeski Y; Kato T; Maeda K; Koizumi K; Monden M; Ohue M; Higashino M; Tanigawa M; Fukunaga M; Kato T; Okamura S; Kimura H; Okajima M; Takakura N; Tanada M; Shirouzu K; Kitano S
  •  go-up   go-down


9. Roohipour R, Patil S, Goodman KA, Minsky BD, Wong WD, Guillem JG, Paty PB, Weiser MR, Neuman HB, Shia J, Schrag D, Temple LK: Squamous-cell carcinoma of the anal canal: predictors of treatment outcome. Dis Colon Rectum; 2008 Feb;51(2):147-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous-cell carcinoma of the anal canal: predictors of treatment outcome.
  • PURPOSE: The incidence of anal canal squamous-cell carcinoma is increasing.
  • METHODS: Using one database, we identified 131 Stages I-III patients treated for primary anal canal squamous-cell carcinoma at our institution from December 1986 to August 2006, with minimum six-month follow-up.
  • RESULTS: Of 131 patients (median age, 58.3 years; median follow-up, 2.9 (range, 0.6-11.2) years), 66 percent were females, 43.5 percent were Stage II, and 11 (8 percent) were HIV-positive.
  • Almost all patients undergoing radiotherapy (96.7 percent, 118/122) also had chemotherapy: 118 (100 percent, Stages I-III) had concurrent chemotherapy: (98 (83.8 percent) mitomycin/5-fluorouracil, 12 (10.2 percent) cisplatin/5-fluorouracil, 8 (6.8 percent) 5-fluorouracil alone); 35 of 46 (76 percent) Stage III patients received induction chemotherapy (34 (97.1 percent) cisplatin/5-fluorouracil, 1 (2.8 percent) 5-fluorouracil alone).
  • Many (44 percent Stages I/II, 48.9 percent Stage III) required dose adjustments.
  • Bivariate analyses demonstrated that T stage (P=0.0019), completion of radiotherapy, and total radiotherapy dose (P=0.03) were all significantly associated with treatment failure.
  • On multivariate analyses, disease stage (P=0.05) and completion of radiotherapy (P=0.01) remained significant predictors of relapse-free survival.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Dis Colon Rectum. 2008 May;51(5):620
  • (PMID = 18180997.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, Halverson AL: Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States. Ann Surg Oncol; 2008 Jul;15(7):1948-58
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the anal canal: utilization and outcomes of recommended treatment in the United States.
  • BACKGROUND: Over the past two decades, recommended treatment for squamous cell carcinoma of the anal canal has shifted from surgery to primary chemoradiation.
  • METHODS: From the National Cancer Data Base (1985-2005), 38,882 patients with anal canal cancer were identified.
  • Patients were significantly less likely to receive guideline treatment if male, older, black or Hispanic, more severe comorbidities, or Stage I (vs Stage II or III).
  • [MeSH-major] Anus Neoplasms / therapy. Neoplasms, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414951.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Bilimoria KY, Bentrem DJ, Rock CE, Stewart AK, Ko CY, Halverson A: Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base. Dis Colon Rectum; 2009 Apr;52(4):624-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base.
  • PURPOSE: The objective of this study was to assess survival and prognostic factors for anal carcinoma in the population.
  • METHODS: Patients with squamous-cell carcinoma of the anal canal were identified from the National Cancer Data Base (1985-2000).
  • Concordance was calculated to assess agreement between American Joint Committee on Cancer stage and actual outcome.
  • RESULTS: Nineteen thousand one hundred ninety-nine patients with anal carcinoma were identified (Stage I, 25.3 percent; Stage II, 51.8 percent; Stage III, 17.1 percent; Stage IV, 5.7 percent).
  • The American Joint Committee on Cancer (6th edition) staging system provided good survival discrimination by stage: I, 69.5 percent; II, 59.0 percent; III, 40.6 percent; and IV, 18.7 percent (concordance index, 0.663).
  • On multivariable analysis, patients with anal carcinoma had a higher risk of death if they were male, >or=65 years old, black, living in lower median incomes areas, and had more advanced T stage tumors, nodal or distant metastases, or poorly differentiated cancers (P < 0.0001).
  • CONCLUSION: Although tumor characteristics and staging affect prognosis, patient factors, such as gender, race, and socioeconomic status, are also important prognostic factors for squamous-cell carcinoma of the anal canal.
  • [MeSH-major] Anus Neoplasms / mortality. Carcinoma, Squamous Cell / mortality

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404066.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Nguyen BT, Joon DL, Khoo V, Quong G, Chao M, Wada M, Joon ML, See A, Feigen M, Rykers K, Kai C, Zupan E, Scott A: Assessing the impact of FDG-PET in the management of anal cancer. Radiother Oncol; 2008 Jun;87(3):376-82
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the impact of FDG-PET in the management of anal cancer.
  • PURPOSE: To assess the utility of FDG-PET in anal cancer for staging and impact on radiotherapy planning (RTP), response and detection of recurrent disease.
  • METHODS AND MATERIALS: Fifty histopathological anal cancer patients were reviewed between 1996 and 2006.
  • RESULTS: The non-PET staging was Stage I(8), Stage II(18), Stage III(22), and Stage IV(2)s.
  • CONCLUSIONS: Anal cancer is FDG-PET avid.
  • PET can aid in anal cancer staging and identification of residual disease, recurrent/metastatic disease but warrants further prospective studies.
  • [MeSH-major] Anus Neoplasms / radionuclide imaging. Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18453023.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


13. Rabbani AN, Zlotecki RA, Kirwan J, George TJ Jr, Morris CG, Rout WR, Mendenhall WM: Definitive radiotherapy for squamous cell carcinoma of the anal canal. Am J Clin Oncol; 2010 Feb;33(1):47-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Definitive radiotherapy for squamous cell carcinoma of the anal canal.
  • PURPOSE: To review the outcomes of definitive radiotherapy (RT) alone or combined with chemotherapy (CT) in the treatment of squamous cell carcinoma of the anal canal.
  • Distribution according to T stage was: T1, 11 (16%); T2, 29 (42%); T3, 21 (30%); and T4, 8 (12%).
  • Distribution according to N stage was: N0, 53 (77%); N1, 3 (4%); N2, 7 (10%); and N3, 6 (9%).
  • The 5-year cause-specific and overall survival rates were: stage I, 100% and 64%; stage II, 86% and 70%; stage III, 80% and 76%; and overall, 87% and 71%, respectively.
  • [MeSH-major] Anal Canal / radiation effects. Antineoplastic Agents / therapeutic use. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Neoplasm Recurrence, Local / diagnosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19704368.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


14. Tajima Y, Ishibashi K, Gonda T, Miyazaki T, Nakada H, Takahashi T, Ishida H: [Squamous cell carcinoma of the anal canal showing complete response following chemoradiotherapy--a case report]. Gan To Kagaku Ryoho; 2007 Nov;34(12):2050-2
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Squamous cell carcinoma of the anal canal showing complete response following chemoradiotherapy--a case report].
  • We report a case of squamous cell carcinoma of the anal canal which showed complete response following chemoradiotherapy.
  • A 54-year-old woman was diagnosed as having squamous cell carcinoma of the anal canal (T2N0M0 stage II).
  • This case suggests that we should take measures to prevent distant metastases in the treatment of squamous cell carcinoma of the anal canal.
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219895.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Fallai C, Cerrotta A, Valvo F, Badii D, Olmi P: Anal carcinoma of the elderly treated with radiotherapy alone or with concomitant radio-chemotherapy. Crit Rev Oncol Hematol; 2007 Mar;61(3):261-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinoma of the elderly treated with radiotherapy alone or with concomitant radio-chemotherapy.
  • PURPOSE: To analyse the results achieved with radio-chemotherapy (RTCT) or radiotherapy alone (RT) in elderly patients (pts) affected with squamous cell anal cancer.
  • There were 9 stage I, 29 stage II, 11 stage IIIa and 13 stage IIIb.
  • RESULTS: Stage II fared significantly better than stage III in terms of locoregional control (LRC) but not overall survival (OS).
  • [MeSH-major] Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17085056.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


16. Blazy A, Hennequin C, Gornet JM, Furco A, Gérard L, Lémann M, Maylin C: Anal carcinomas in HIV-positive patients: high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy. Dis Colon Rectum; 2005 Jun;48(6):1176-81
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal carcinomas in HIV-positive patients: high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy.
  • BACKGROUND: Anal carcinoma, a common disease in HIV-positive patients, is usually treated with chemoradiotherapy.
  • We report our experience of treating anal carcinoma in the era of new antiviral drugs.
  • PATIENTS AND METHODS: Between 1997 and 2001, nine men on highly active antiretroviral therapies with good immune status before chemoradiotherapy received concomitant chemoradiotherapy consisting of 5-fluorouracil and cisplatinum, and high-dose radiotherapy (60-70 Gy) for anal carcinoma.
  • Six cancers were Stage I, two were Stage II, and one was Stage III.
  • Among them, four had no or minor anal function impairment at the last follow-up visit.
  • CONCLUSION: High-dose chemoradiotherapy for anal carcinomas is feasible with low toxicity in HIV-positive patients treated with highly active antiretroviral therapies.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. Cisplatin / administration & dosage. Fluorouracil / administration & dosage. HIV Infections / complications

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15906137.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Djellali L, Larbaoui B, Boukerche A, Ghazi S, Chaiba I, Meziane N, Yekrou D, Youcef DF: Preoperative concomitant chemoradiotherapy with oxaliplatin and 5-fluorouracil in locally advanced rectal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative concomitant chemoradiotherapy with oxaliplatin and 5-fluorouracil in locally advanced rectal carcinoma.
  • : e15108 Background: Preoperative concomitant chemoradiotherapy has shown to improve local control and sphincter preservation with decreased acute toxicity compared with postoperative treatment in locally advanced rectal carcinoma.
  • The primary endpoint of this phase II trial was pathologic tumor response.
  • Secondary endpoint was sphincter preservation and toxicity Methods: Inclusion criteria: rectal adenocarcinoma <12 cms from anal verge, clinical stage T3-4, adequate renal, hematological and liver function.
  • Clinical stage (determined by CT or RMI): T3: 66.6% and T4: 33.3%.
  • Tumor location (from anal verge): < 6 cm in 10pts, >6 cm in 5pts.
  • Main adverse effects (NCI-CTC): diarrhea G3-4: 14.2%, sensitive peripheral neurotoxicity G1: 26.6%, nausea/vomiting G3-4: 11%, Anemia G3-4: 7.1%, neutropenia G3-4: 14.2% Conclusions: Preliminary results show that preoperative concomitant chemoradiotherapy with oxaliplatin and 5FU-folinic acid is an effective regimen with an acceptable safety profile for locally advanced rectal cancer, leading to a high probability of tumor downstaging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964340.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Swampillai A, Williams M, Osborne M, Mawdsley S, Hughes R, Harrison M, Glynne-Jones R: A single-center study of the utility of squamous cell carcinoma antigen (SCCAg) levels in epidermoid carcinoma of the anal canal and margin (ECACM) treated with chemoradiation (CRT). J Clin Oncol; 2009 May 20;27(15_suppl):4117

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single-center study of the utility of squamous cell carcinoma antigen (SCCAg) levels in epidermoid carcinoma of the anal canal and margin (ECACM) treated with chemoradiation (CRT).
  • Radiotherapy comprised the schedule of the UK Anal cancer Trial (ACT II).
  • Clinical stage at diagnosis- Tx (6) T1 (28), T2 (80), T3 (65), T4 (16), N0 (126), N+ (66) Nx (3).
  • RESULTS: Mean baseline SCCAg by cT and cN stage were: T1 93 (ng/dl), T2 300, T3 607, T4 882, N0 376, N+ 529 (correlation coeff: T: 0.47, N: 0.33, both p< 0.001).
  • CONCLUSIONS: There is a correlation between T and N stage and baseline SCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961219.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Eng C, Chang GJ, Das P, Rodriguez-Bigas M, Skibber JM, Qiao W, Rosner GL, Ukegbu LT, Wolff RA, Crane CH: Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal. J Clin Oncol; 2009 May 20;27(15_suppl):4116

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal.
  • : 4116 Background: Definitive therapy for squamous cell carcinoma (SCC) of the anal canal consists of external beam radiotherapy with concurrent 5-fluorouracil and mitomycin C or cisplatin.
  • The purpose of this study was to evaluate the tolerability and efficacy of XELOX-XRT as definitive treatment for anal cancer.
  • METHODS: Patients with histologically proven SCC of the anal canal, AJCC Stage II-IIIB (T<sub>2-4</sub> or N+M<sub>0</sub>), ECOG PS 0-1, HIV<sup>-</sup>, and no prior therapy were eligible for XELOX-based chemoradiotherapy.
  • CONCLUSIONS: The combination of capecitabine, oxaliplatin, and radiation therapy (XELOX-XRT) is effective for locally advanced squamous cell carcinoma of the anal canal.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961220.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Larbaoui B: Preoperative concomitant chemoradiotherapy with capecitabine in locally advanced rectal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15134

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative concomitant chemoradiotherapy with capecitabine in locally advanced rectal carcinoma.
  • : e15134 Background: Preoperative concomitant chemoradiotherapy has shown to improve local control and sphincter preservation with decreased acute toxicity compared with postoperative treatment in locally advanced rectal carcinoma.
  • The primary endpoint of this phase II trial was pathologic tumor response.
  • METHODS: Inclusion criteria: rectal adenocarcinoma <12 cms from anal verge, clinical stage T3-4, adequate renal, hematological and liver function.
  • Clinical stage (determined by CT or RMI): T3: 70% and T4: 30%.
  • Tumor location (from anal verge): < 6 cm in 8pts, >6 cm in 7pts.
  • CONCLUSIONS: Preliminary results show that preoperative concomitant chemoradiotherapy with Capecitabine is an effective regimen with an acceptable safety profile for locally advanced rectal cancer, leading to a high probability of tumor downstaging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960909.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Oehler-Jänne C, Seifert B, Lütolf UM, Studer G, Glanzmann C, Ciernik IF: Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma. Brachytherapy; 2007 Jul-Sep;6(3):218-26
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma.
  • PURPOSE: To evaluate the outcome after definitive whole pelvis external beam radiotherapy (EBRT) followed by brachytherapy (BT) boost after treatment break vs. external beam boost without break in the treatment of anal carcinoma.
  • METHODS AND MATERIALS: Eighty-one consecutive patients with invasive anal carcinoma were analyzed retrospectively.
  • Concomitant chemotherapy (CT) with mitomycin C was applied during whole pelvis EBRT depending on tumor stage.
  • Pattern of care, local disease control (LC), cancer-specific survival (CSS), overall survival (OS), toxicity, and quality of life (QOL) were assessed.
  • In early stage tumors, (192)Ir-HDR BT boost with CT resulted in a 5-year LC and CSS of 100%.
  • In all patients, BT boost did not result in improved LC, OS, and CSS compared with EBRT boost, despite stage and treatment bias favoring small tumors to be treated with BT.
  • Subgroup analysis of Stages I and II disease revealed no significant improvement after BT boost compared with EBRT boost.
  • BT boost is most beneficial in early stage tumors but the advantage of BT seems to be limited due to its invasiveness, doctor dependence, and logistic circumstances.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Brachytherapy / instrumentation. Carcinoma / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17681244.001).
  • [ISSN] 1538-4721
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


22. Ferrigno R, Nakamura RA, Dos Santos Novaes PE, Pellizzon AC, Maia MA, Fogarolli RC, Salvajoli JV, Filho WJ, Lopes A: Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. Int J Radiat Oncol Biol Phys; 2005 Mar 15;61(4):1136-42
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness.
  • PURPOSE: This retrospective analysis reports the results on patients with anal canal carcinoma treated by combined radiotherapy and chemotherapy.
  • METHODS AND MATERIALS: Between March 1993 and December 2001, 43 patients with anal canal carcinoma were treated with radiochemotherapy at the Hospital do Cancer A.C. Camargo.
  • Stage distribution was as follows: I, 3 (7%); II, 23 (53.5%); IIIA, 8 (18.6%); and IIIB, 9 (21%).
  • Patient's age, tumor stage, overall treatment time, and RT dose at primary tumor were variables analyzed for survival and local control.
  • Overall survival according to clinical stage was as follows: I, 100%; II, 82%; IIIA, 73%; and IIIB, 18% (p = 0.0049).
  • CONCLUSIONS: This analysis suggests that the treatment scheme employed was effective for anal sphincter preservation and local control; however, the incidence of distant metastases was relatively high.
  • The clinical stage was the main prognostic factor for overall survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15752894.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


23. Nakagawa S, Amano M, Yamashita S, Nishikawa Y, Higaki N, Hayashida H, Niinobu T, Yoshioka Y, Sakon M: [A case of effective chemoradiation therapy against anal fistula carcinoma recurred 10 years after surgery]. Gan To Kagaku Ryoho; 2006 Nov;33(12):1977-9
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of effective chemoradiation therapy against anal fistula carcinoma recurred 10 years after surgery].
  • A male in his eighties underwent abdominoperineal resection under the diagnosis of adenocarcinoma associated with anal fistula (P0, H0, n (-), A1, stage II, ly0, v0).
  • [MeSH-major] Adenocarcinoma / therapy. Anus Neoplasms / therapy. Rectal Fistula / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17212165.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 1-UFT protocol
  •  go-up   go-down


24. Selvindos PB, Ho YH: Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis. Dis Colon Rectum; 2008 Nov;51(11):1710-1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimedia article. Laparoscopic ultralow anterior resection with colonic J-pouch-anal anastomosis.
  • PURPOSE: Optimal treatment of mid to distal rectal cancers includes total mesorectal excision for oncologic clearance and, where reanastomosis is feasible, a colonic J-pouch-anal anastomosis improves bowel function.
  • Bowel continuity was restored by an intracoporeal double-cross stapled colonic J-pouch-anal anastomosis, but where not possible a coloplasty with pull-through handsewn coloanal anastomosis was performed.
  • The indications were adenocarcinoma (n = 51), squamous-cell carcinoma of rectum (n = 1), dermoid tumor of mesorectum (n = 1), large villous adenoma (n = 1), and carcinoid with local lymph node metastases (n = 1).
  • The adenocarcinomas were a median distance of 6 (3-12) cm from the anal verge.
  • The histologic grading or the adenocarcinoma patients were: Stage I, n = 14; Stage II, n = 23; Stage III, n = 11; Stage IV, n = 3.
  • The level of the coloanal anastomosis was a median 3.5 (0-4.5) cm from the anal verge; a coloanal pull-through anastomosis was required in one patient who had a distal cancer.
  • Four other patients had smaller pelvic collections that resolved with antibiotics; pelvic collections were associated with advanced stage of cancer (P = 0.047).
  • This brought the rectum proximally and anteriorly, aiding with the laparoscopic stapler transection of the distal rectum, especially if the cancer was distal, the patient was obese, and the pelvis was narrow.
  • Further randomized, controlled studies that include assessing five-year cancer survival/recurrence, pelvic nerve dysfunction, and bowel function are needed before laparoscopic ultralow anterior resection becomes widely accepted.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Colonic Pouches. Laparoscopy / methods. Proctocolectomy, Restorative / methods. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18679748.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Interactive Tutorial
  • [Publication-country] United States
  •  go-up   go-down


25. Widder J, Kastenberger R, Fercher E, Schmid R, Langendijk JA, Dobrowsky W, Pötter R: Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients. Radiother Oncol; 2008 Jun;87(3):367-75
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients.
  • BACKGROUND AND PURPOSE: To retrospectively analyse a large consecutive cohort of patients with anal cancer for treatment-related factors influencing local control and survival.
  • MATERIALS AND METHODS: All patients referred for primary radiotherapy at Medical University of Vienna in 1990-2002 with anal canal carcinoma without distant metastases were analysed.
  • RESULTS: Median age was 67 years (n=129), the UICC stage distribution was 15%, 58%, and 27% for stages I, II, and III, respectively.
  • Stage and age were significant factors for overall and colostomy-free-survival, N-stage for disease-free-survival.
  • Shorter overall treatment time favoured local control in stage T1-2 (p=.015), higher total radiation dose and female gender were associated with improved local control in T3-4 tumours (p=.021).
  • CONCLUSIONS: These results support potential improvement of anal cancer treatment by studying advanced technology such as IMRT, making it possible to tailor high-dose regions.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18501453.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


26. Pucciarelli S, Capirci C, Emanuele U, Toppan P, Friso ML, Pennelli GM, Crepaldi G, Pasetto L, Nitti D, Lise M: Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer. Ann Surg Oncol; 2005 Feb;12(2):111-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer.
  • BACKGROUND: We investigated the relationship between pathologic T-stage and mesorectal metastases after preoperative chemoradiotherapy (CRT) for clinical stage II to III rectal carcinoma.
  • METHODS: The records of consecutive patients with clinical stage II to III carcinoma of the mid or low rectum who underwent surgery after CRT were reviewed.
  • Indications for preoperative CRT were cancer up to 11 cm from the anal verge, Eastern Cooperative Oncology Group performance status of 0 to 2, age 18 to 75 years, and clinical tumor-node-metastasis stage II or III.
  • The pretreatment tumor-node-metastasis stage was as follows: I, n = 1; II, n = 96; and III, n = 138.
  • According to the pT stage, the rate of node positivity was 2% for pT0, 15% for pT1, 17% for pT2, 38% for pT3, and 33% for pT4 cases.
  • On considering pT stage alone, the odds ratio was in the region of 10 for pT1/2 and >20 for pT3/4 patients.
  • CONCLUSIONS: In patients with pT0 after preoperative CRT for clinical stage II to III mid or low rectal cancer, the risk of nodal metastases is very low.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2005 Feb;12(2):95-7 [15827785.001]
  • (PMID = 15827790.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


27. Piperkova E, Raphael B, Altinyay M, Castellon I, Libes R, Sandella N, Abdel-Dayem H: Impact of PET/CT on initial staging, restaging and treatment management of anal cancer: a clinical case with literature review. J BUON; 2006 Oct-Dec;11(4):523-7
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of PET/CT on initial staging, restaging and treatment management of anal cancer: a clinical case with literature review.
  • Distant extrapelvic metastases appear in approximately in 10% of the patients with squamous cell anal cancer (SCAC) and survival depends on the treatment strategy.
  • We present a patient with SCAC in whom, according to PET/CT findings, the initial stage was changed from II (T2N0M0) to III A (T2N2M0).
  • Radiation therapy (RT) and chemotherapy achieved a good therapeutic response but early follow up revealed new paraaortic lymph node (LN) metastases, as well as an uncommon left supraclavicular LN metastasis from the same primary carcinoma.
  • The disease was restaged as stage IV (T2N2M1) and radiation therapy was substituted by chemotherapy.
  • [MeSH-major] Anus Neoplasms / radiography. Anus Neoplasms / radionuclide imaging. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309188.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


28. Garlipp B, Ptok H, Schmidt U, Meyer F, Gastinger I, Lippert H: Neoadjuvant chemoradiotherapy for rectal carcinoma: effects on anastomotic leak rate and postoperative bladder dysfunction after non-emergency sphincter-preserving anterior rectal resection. Results of the Quality Assurance in Rectal Cancer Surgery multicenter observational trial. Langenbecks Arch Surg; 2010 Nov;395(8):1031-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemoradiotherapy for rectal carcinoma: effects on anastomotic leak rate and postoperative bladder dysfunction after non-emergency sphincter-preserving anterior rectal resection. Results of the Quality Assurance in Rectal Cancer Surgery multicenter observational trial.
  • INTRODUCTION: Randomized trials have demonstrated a reduction in local recurrence rate in rectal cancer patients treated with preoperative chemoradiotherapy and total mesorectal excision (TME) compared to patients undergoing TME alone.
  • Accordingly, preoperative chemoradiotherapy in all UICC stages II and III rectal cancers has been recommended in the German treatment guidelines as of 2004.
  • It was the aim of our analysis to investigate the influence of preoperative chemoradiotherapy on anastomotic leak rate and postoperative bladder dysfunction in rectal cancer patients using a representative data set from the Quality Assurance in Rectal Cancer Surgery multicenter observational trial.
  • METHOD: This is a retrospective analysis of data from the Quality Assurance in Rectal Cancer Surgery prospective multicenter observational trial.
  • Data of all patients undergoing curatively intended sphincter-preserving resection for UICC stage I through III rectal carcinoma between 01 Jan 2005 and 31 Dec 2007 with or without preoperative chemoradiotherapy (groups A and B, respectively) were included.
  • RESULTS: A total of 2,085 patients were included (group A, n = 676, group B, n = 1,409).
  • Significant differences were present between groups regarding age, sex, distance of the tumor from the anal verge, pT-stage, UICC stage, hepatic risk factors, and use of protective enterostomy by univariate analysis.
  • CONCLUSION: Neoadjuvant chemoradiotherapy for rectal carcinoma does not increase the risk for anastomotic leakage or postoperative bladder dysfunction after curatively intended sphincter-preserving rectal resection.


29. Dietz DW, Dehdashti F, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, Ritter J, Lewis JS, Welch MJ, Siegel BA: Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum; 2008 Nov;51(11):1641-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study.
  • METHODS: Patients with locally invasive (T2-4) primary or node-positive rectal cancer located <12 cm from the anal verge were recruited for this pilot study.
  • Pretreatment tumor size and stage were determined by endorectal ultrasonography, CT, and magnetic resonance imaging.
  • The median tumor-to-muscle activity ratio of 2.6 discriminated those with worse prognosis from those with better prognosis.
  • In addition, 2 of the 3 tumors with no change in size had tumor-to-muscle activity ratios >2.6 (positive predictive value 66 percent), whereas 6 of 14 with decreased size had tumor-to-muscle activity ratios >2.6 (negative predictive value 57 percent).
  • CONCLUSIONS: The results of this small pilot study suggest that (60)Cu-ATSM-PET may be predictive of survival and, possibly, tumor response to neoadjuvant chemoradiotherapy in patients with rectal cancer.
  • A larger Phase II study is warranted to validate these results.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / therapy. Organometallic Compounds. Positron-Emission Tomography. Rectal Neoplasms / diagnosis. Rectal Neoplasms / therapy. Thiosemicarbazones

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18682881.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R24 CA086307
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organometallic Compounds; 0 / Thiosemicarbazones; 0 / copper (II) diacetyl-di(N(4)-methylthiosemicarbazone)
  • [Other-IDs] NLM/ NIHMS802312; NLM/ PMC4962601
  •  go-up   go-down


30. Du J, Yang S, Lin X, Bu L, Nan Y, Huo S, Shang W: Use of anchorchip-time-of-flight spectrometry technology to screen tumor biomarker proteins in serum for small cell lung cancer. Diagn Pathol; 2010;5:60
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of anchorchip-time-of-flight spectrometry technology to screen tumor biomarker proteins in serum for small cell lung cancer.
  • BACKGROUND: The purpose of this study is to discover potential biomarkers in serum for the detection of small cell lung cancer (SCLC).
  • Remarkably, 88.89% of stage I/II patients were accurately assigned to SCLC.
  • [MeSH-major] Biomarkers, Tumor / blood. Lung Neoplasms / blood. Neoplasm Proteins / blood. Proteomics / methods. Small Cell Lung Carcinoma / blood. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chem. 2002 Aug;48(8):1296-304 [12142387.001]
  • [Cites] Anal Chem. 2004 Mar 15;76(6):1560-70 [15018552.001]
  • [Cites] J Proteome Res. 2004 Nov-Dec;3(6):1261-6 [15595736.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Feb 5;815(1-2):169-78 [15652807.001]
  • [Cites] Hepatology. 2005 Mar;41(3):634-42 [15726646.001]
  • [Cites] Eur Urol. 2005 Apr;47(4):456-62 [15774241.001]
  • [Cites] Laryngoscope. 2008 Jan;118(1):61-8 [18043497.001]
  • [Cites] Oncologist. 2005 Jun-Jul;10(6):399-411 [15967834.001]
  • [Cites] BMC Cancer. 2005;5:83 [16029516.001]
  • [Cites] J Clin Invest. 2006 Jan;116(1):271-84 [16395409.001]
  • [Cites] Trends Pharmacol Sci. 2006 May;27(5):251-9 [16600386.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1068-76 [16603345.001]
  • [Cites] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2007 Aug;23(8):751-3 [17618570.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2575-83 [15880380.001]
  • (PMID = 20854674.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2955651
  •  go-up   go-down


31. Kato T, Takagi H, Mori Y, Sakamoto K, Yamada T, Umeda Y, Fukumoto Y, Hirose H: Simultaneous operation of ischemic heart disease, abdominal aortic aneurysm, and rectal cancer. Heart Vessels; 2005 Jul;20(4):167-70
Genetic Alliance. consumer health - Abdominal Aortic Aneurysm.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous operation of ischemic heart disease, abdominal aortic aneurysm, and rectal cancer.
  • A 68-year-old man with ischemic heart disease, abdominal aortic aneurysm, and rectal cancer was referred.
  • Barium enema revealed stenosis 4 cm in length 5 cm inward from the anal verge, and an endoscopic finding was ulcerated type tumor with a clear margin and circumferential stenosis.
  • Histological examination of a biopsy specimen revealed adenocarcinoma, and the clinical stage in the Japanese classification of colorectal carcinoma was II according to other examinations.
  • Simultaneous operations were scheduled because of the jeopardized collaterals of the coronary arteries, rapid expansion of the aneurysm, and subileus due to the cancer.
  • The patient is doing well 12 months after the operation, without myocardial ischemic symptoms or recurrence of the cancer.

  • Genetic Alliance. consumer health - Heart Disease.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16025367.001).
  • [ISSN] 0910-8327
  • [Journal-full-title] Heart and vessels
  • [ISO-abbreviation] Heart Vessels
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


32. Saleh F, Abdeen S: Pathobiological features of breast tumours in the State of Kuwait: a comprehensive analysis. J Carcinog; 2007;6:12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Breast cancer accounts for 30.3% of all cancer types in Kuwaiti women.
  • Grading of invasive carcinomas was done according to the modified Bloom-Richardson-Elston's method, and tumour stage was determined according to the criteria set by the American Joint Committee on Cancer.
  • They were mostly grade II or III, sized 2-5 or > 5 cm, had absent or scanty tumour lymphocytes, and were stage II or III.
  • The in situ tumours were mainly ductal carcinoma (DCIS) of which comedo and cribriform were the major histological subtypes.
  • CONCLUSION: Breast cancer in Kuwait seems to be more aggressive than what is currently seen in Europe, North America, Australia, and parts of Asia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1998 Feb;11(2):155-68 [9504686.001]
  • [Cites] J Surg Oncol. 2004 Jun 1;86(3):134-40 [15170651.001]
  • [Cites] Breast Cancer Res Treat. 1998;51(3):195-208 [10068079.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):26-35 [15332092.001]
  • [Cites] Eur J Cancer Prev. 2004 Aug;13(4):307-17 [15554559.001]
  • [Cites] Am Surg. 2005 Jan;71(1):22-7; discussion 27-8 [15757052.001]
  • [Cites] Kaohsiung J Med Sci. 2005 May;21(5):197-202 [15960065.001]
  • [Cites] Breast Cancer Res. 2005;7(4):R541-54 [15987461.001]
  • [Cites] Br J Dermatol. 2005 Jul;153(1):18-21 [16029321.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3c):2535-42 [16080489.001]
  • [Cites] J Reprod Immunol. 2005 Oct;67(1-2):35-50 [16111767.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R598-604 [16168103.001]
  • [Cites] Acta Oncol. 1990;29(7):931-4 [1979748.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):944-8 [1988136.001]
  • [Cites] Acta Oncol. 1990;29(2):129-35 [2334566.001]
  • [Cites] Acta Oncol. 1989;28(6):807-10 [2611034.001]
  • [Cites] Aust N Z J Med. 1978 Dec;8(6):630-8 [285684.001]
  • [Cites] BMJ. 1988 Oct 15;297(6654):943-8 [3142562.001]
  • [Cites] Acta Pathol Jpn. 1984 Mar;34(2):229-39 [6331061.001]
  • [Cites] J Clin Oncol. 1984 Oct;2(10):1102-9 [6491696.001]
  • [Cites] Hum Pathol. 1983 Apr;14(4):368-72 [6832775.001]
  • [Cites] Hum Pathol. 1995 Aug;26(8):873-9 [7635449.001]
  • [Cites] Breast Cancer Res Treat. 1995 Aug;35(2):201-10 [7647342.001]
  • [Cites] Semin Diagn Pathol. 1994 Aug;11(3):208-14 [7831532.001]
  • [Cites] Anal Quant Cytol Histol. 1994 Jun;16(3):203-10 [7916848.001]
  • [Cites] Surgery. 1994 Oct;116(4):605-8; discussion 608-9 [7940156.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):23-33 [8083119.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):156-61 [8100443.001]
  • [Cites] Hematol Oncol Clin North Am. 1994 Feb;8(1):73-100 [8150784.001]
  • [Cites] Am J Surg. 1993 Mar;165(3):307-11 [8447534.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2894-904 [9256133.001]
  • [Cites] AJR Am J Roentgenol. 1998 Jan;170(1):97-104 [9423608.001]
  • [Cites] Stem Cells. 1998;16(6):413-28 [9831867.001]
  • [Cites] Oncol Rep. 1999 Jan-Feb;6(1):135-8 [9864416.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):2011-7 [10213514.001]
  • [Cites] Ontogenez. 1999 Mar-Apr;30(2):130-3 [10368823.001]
  • [Cites] Mod Pathol. 1999 Aug;12(8):827-34 [10463486.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):855-61 [10548312.001]
  • [Cites] Oncol Rep. 2000 Mar-Apr;7(2):295-8 [10671674.001]
  • [Cites] Am J Surg. 2000 Feb;179(2):81-5 [10773138.001]
  • [Cites] J Clin Pathol. 2000 Sep;53(9):688-96 [11041059.001]
  • [Cites] Int J Cancer. 2002 Apr 10;98(5):754-60 [11920647.001]
  • [Cites] Oncol Rep. 2002 Sep-Oct;9(5):1053-7 [12168072.001]
  • [Cites] Breast Cancer Res Treat. 2002 Dec;76(3):221-36 [12462383.001]
  • [Cites] Eur J Cancer. 2003 Mar;39(5):622-30 [12628841.001]
  • [Cites] Jpn J Clin Oncol. 2003 Feb;33(2):61-7 [12629055.001]
  • [Cites] Oncol Rep. 2003 Sep-Oct;10(5):1321-8 [12883701.001]
  • [Cites] Endocr Rev. 1992 Feb;13(1):3-17 [1313356.001]
  • [Cites] Br J Cancer. 1992 Oct;66(4):610-3 [1419596.001]
  • [Cites] Curr Opin Obstet Gynecol. 2004 Feb;16(1):49-55 [15128008.001]
  • [Cites] Breast Cancer Res Treat. 1998;52(1-3):305-19 [10066089.001]
  • (PMID = 17892570.001).
  • [ISSN] 1477-3163
  • [Journal-full-title] Journal of carcinogenesis
  • [ISO-abbreviation] J Carcinog
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2169224
  •  go-up   go-down


33. Verona EV, Tang Y, Millstead TK, Hinck AP, Agyin JK, Sun LZ: Expression, purification and characterization of BG(E)RII: a novel pan-TGFbeta inhibitor. Protein Eng Des Sel; 2008 Jul;21(7):463-73
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This involvement in late-stage carcinoma and pathological fibrosis makes TGFbeta isoforms prime targets for therapeutic intervention.
  • Although soluble ectodomains of TGFbeta type II (RII) and betaglycan (BG) have been utilized as TGFbeta inhibitors, their antagonistic potency against different TGFbeta isoforms varies considerably because RII does not appreciably bind to TGFbeta2 whereas BG binds weakly to TGFbeta1 and TGFbeta3.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Microbes Infect. 1999 Dec;1(15):1327-47 [10611761.001]
  • [Cites] Cancer Res. 2002 Aug 15;62(16):4690-5 [12183427.001]
  • [Cites] Am J Reprod Immunol. 2002 Dec;48(6):387-93 [12607775.001]
  • [Cites] Kidney Int. 2003 Sep;64(3):844-56 [12911534.001]
  • [Cites] J Med Chem. 2003 Sep 11;46(19):3953-6 [12954047.001]
  • [Cites] Bioorg Med Chem Lett. 2003 Dec 15;13(24):4355-9 [14643325.001]
  • [Cites] Mol Carcinog. 2004 Jun;40(2):116-21 [15170816.001]
  • [Cites] Biochem Pharmacol. 2004 Jul 1;68(1):41-50 [15183116.001]
  • [Cites] Arthritis Rheum. 2004 Jun;50(6):1822-31 [15188359.001]
  • [Cites] J Mol Biol. 2005 Dec 16;354(5):1052-68 [16289576.001]
  • [Cites] J Mol Biol. 2006 Jan 6;355(1):47-62 [16300789.001]
  • [Cites] Alcohol Clin Exp Res. 2005 Nov;29(11 Suppl):121S-131S [16344596.001]
  • [Cites] Cardiovasc Res. 2006 Feb 1;69(2):432-9 [16360132.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):129-39 [16377233.001]
  • [Cites] J Biol Chem. 2006 Jun 23;281(25):17011-22 [16621788.001]
  • [Cites] Curr Opin Investig Drugs. 2006 Jun;7(6):513-21 [16784021.001]
  • [Cites] Proc Am Thorac Soc. 2006 Jul;3(5):413-7 [16799084.001]
  • [Cites] Cancer Lett. 2006 Nov 8;243(1):16-22 [16388897.001]
  • [Cites] Curr Opin Rheumatol. 2006 Nov;18(6):582-7 [17053502.001]
  • [Cites] Curr Cancer Drug Targets. 2006 Nov;6(7):565-78 [17100564.001]
  • [Cites] J Clin Invest. 2007 Jan;117(1):206-17 [17160136.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1090-8 [17283142.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5737-46 [17575140.001]
  • [Cites] World J Gastroenterol. 2007 Jun 14;13(22):3056-62 [17589920.001]
  • [Cites] J Biol Chem. 2008 Mar 21;283(12):7628-37 [18184661.001]
  • [Cites] J Biol Chem. 2008 Mar 28;283(13):8412-22 [18204048.001]
  • [Cites] J Biol Chem. 2004 Jun 18;279(25):26013-8 [15044491.001]
  • [Cites] J Dermatol Sci. 2004 Jun;35(1):9-18 [15194142.001]
  • [Cites] J Med Chem. 2004 Aug 26;47(18):4494-506 [15317461.001]
  • [Cites] Mol Vis. 2004 Oct 4;10:703-11 [15475878.001]
  • [Cites] Nature. 1987 Oct 8-14;329(6139):539-41 [2889143.001]
  • [Cites] J Biol Chem. 1990 Nov 25;265(33):20533-8 [1700790.001]
  • [Cites] Mol Endocrinol. 1991 Dec;5(12):1887-96 [1665203.001]
  • [Cites] Cell. 1993 Jul 2;73(7):1435-44 [8391934.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):368-80 [8342593.001]
  • [Cites] J Biol Chem. 1993 Oct 25;268(30):22710-5 [8226781.001]
  • [Cites] J Cell Biol. 1994 Feb;124(4):557-68 [8106553.001]
  • [Cites] Anal Biochem. 1994 Feb 1;216(2):276-84 [8179182.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 19;91(15):6997-7001 [8041735.001]
  • [Cites] FEBS Lett. 1995 Dec 27;377(3):368-72 [8549757.001]
  • [Cites] FASEB J. 1996 Jan;10(1):49-56 [8566547.001]
  • [Cites] Prostate. 1997 Oct 1;33(2):133-40 [9316654.001]
  • [Cites] Eur J Biochem. 1998 Jun 15;254(3):505-13 [9688260.001]
  • [Cites] Annu Rev Biochem. 1998;67:753-91 [9759503.001]
  • [Cites] Curr Opin Biotechnol. 1998 Oct;9(5):497-501 [9821278.001]
  • [Cites] Circ Res. 1999 May 28;84(10):1212-22 [10347096.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):5041-6 [10519421.001]
  • [Cites] J Cell Physiol. 2005 Feb;202(2):361-70 [15389580.001]
  • [Cites] Nat Rev Drug Discov. 2004 Dec;3(12):1011-22 [15573100.001]
  • [Cites] Prostate. 2005 Apr 1;63(1):81-90 [15468171.001]
  • [Cites] J Biochem Mol Biol. 2005 Jan 31;38(1):1-8 [15715939.001]
  • [Cites] Clin Cancer Res. 2005 Jun 15;11(12):4512-20 [15958637.001]
  • [Cites] Ann Pharmacother. 2005 Dec;39(12):2136-8 [16288076.001]
  • [Cites] Genes Dev. 2005 Dec 1;19(23):2783-810 [16322555.001]
  • [Cites] Hum Gene Ther. 2000 Jan 1;11(1):33-42 [10646637.001]
  • [Cites] Kidney Int. 2000 Mar;57(3):937-48 [10720947.001]
  • [Cites] N Engl J Med. 2000 May 4;342(18):1350-8 [10793168.001]
  • [Cites] Biochem J. 2001 Apr 1;355(Pt 1):215-22 [11256966.001]
  • [Cites] J Biol Chem. 2001 May 4;276(18):14588-96 [11278442.001]
  • [Cites] J Biol Chem. 2001 Aug 10;276(32):29632-43 [11382746.001]
  • [Cites] Am J Respir Crit Care Med. 2002 Feb 1;165(3):419-23 [11818331.001]
  • [Cites] Oncogene. 2002 May 16;21(22):3541-51 [12032856.001]
  • [Cites] J Clin Invest. 2002 Jun;109(12):1607-15 [12070308.001]
  • [Cites] Biochem Cell Biol. 2002;80(5):605-22 [12440701.001]
  • (PMID = 18499679.001).
  • [ISSN] 1741-0126
  • [Journal-full-title] Protein engineering, design & selection : PEDS
  • [ISO-abbreviation] Protein Eng. Des. Sel.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA040035-190014; United States / NCI NIH HHS / CA / P01 CA040035; United States / NCI NIH HHS / CA / P01 CA040035-190014; United States / NCI NIH HHS / CA / R01 CA075253; United States / NCI NIH HHS / CA / R01 CA075253-11A1; United States / NCI NIH HHS / CA / CA075253-11A1; United States / NCI NIH HHS / CA / P01CA40035; United States / NCI NIH HHS / CA / R01CA75253
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Fusion Proteins; 0 / Smad2 Protein; 0 / Smad3 Protein; 0 / Transforming Growth Factor beta
  • [Other-IDs] NLM/ NIHMS52143; NLM/ PMC2575055
  •  go-up   go-down


34. Meyer-Siegler KL, Cox J, Leng L, Bucala R, Vera PL: Macrophage migration inhibitory factor anti-thrombin III complexes are decreased in bladder cancer patient serum: Complex formation as a mechanism of inactivation. Cancer Lett; 2010 Apr 1;290(1):49-57
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Macrophage migration inhibitory factor anti-thrombin III complexes are decreased in bladder cancer patient serum: Complex formation as a mechanism of inactivation.
  • Serum MIF in bladder cancer patients (TCC stage II, n=50) was increased when compared to normal patients (n=50), while ATIII-MIF complexes were decreased in bladder cancer patient serum.
  • These data suggest that increased circulating levels of bioactive MIF are present in bladder cancer patient serum.

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Ireland Ltd.
  • [Cites] Nat Med. 2000 Feb;6(2):164-70 [10655104.001]
  • [Cites] Mediators Inflamm. 2009;2009:535348 [19325914.001]
  • [Cites] Transplantation. 2001 Jun 27;71(12):1777-83 [11455258.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1449-56 [11920501.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4015-20 [12010802.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):2053-63 [12466122.001]
  • [Cites] Trends Cardiovasc Med. 2002 Nov;12(8):331-8 [12536119.001]
  • [Cites] Immunol Cell Biol. 2003 Apr;81(2):137-43 [12631237.001]
  • [Cites] Expert Opin Ther Targets. 2003 Apr;7(2):153-64 [12667094.001]
  • [Cites] J Endotoxin Res. 2003;9(2):119-23 [12803886.001]
  • [Cites] Anal Chem. 2003 Sep 1;75(17):4646-58 [14632076.001]
  • [Cites] J Biol Chem. 2004 Apr 2;279(14):13729-37 [14736878.001]
  • [Cites] BMC Cancer. 2004 Jul 12;4:34 [15248897.001]
  • [Cites] J Urol. 2004 Oct;172(4 Pt 1):1504-9 [15371880.001]
  • [Cites] Am J Clin Pathol. 1978 Feb;69(2):194-5 [629228.001]
  • [Cites] J Clin Pathol. 1979 Jan;32(1):21-5 [429575.001]
  • [Cites] Thromb Haemost. 1981 Aug 28;46(2):500-3 [7302888.001]
  • [Cites] J Urol. 1982 Jul;128(1):72-4 [7109075.001]
  • [Cites] Am J Med. 1989 Sep 11;87(3B):10S-14S [2552799.001]
  • [Cites] Thromb Haemost. 1996 Dec;76(6):897-901 [8972008.001]
  • [Cites] J Biol Chem. 1997 Aug 1;272(31):19393-400 [9235938.001]
  • [Cites] Int J Hematol. 1998 Jul;68(1):67-78 [9713170.001]
  • [Cites] BMC Cancer. 2005;5:73 [16000172.001]
  • [Cites] J Biol Chem. 2005 Nov 4;280(44):36541-4 [16115897.001]
  • [Cites] Eur J Immunol. 2005 Dec;35(12):3405-13 [16224818.001]
  • [Cites] World J Gastroenterol. 2006 Jan 7;12(1):60-5 [16440418.001]
  • [Cites] J Urol. 2006 Apr;175(4):1523-8 [16516040.001]
  • [Cites] J Immunol. 2006 Dec 15;177(12):8730-9 [17142775.001]
  • [Cites] Oncogene. 2007 May 14;26(22):3100-12 [17496909.001]
  • [Cites] Mol Endocrinol. 2007 Jun;21(6):1267-80 [17389748.001]
  • [Cites] Autoimmun Rev. 2007 Nov;7(1):8-11 [17967718.001]
  • [Cites] Electrophoresis. 2007 Dec;28(23):4302-10 [18041032.001]
  • [Cites] Intensive Care Med. 2008 Feb;34(2):361-7 [17940748.001]
  • [Cites] Inflamm Res. 2008 Feb;57(2):45-50 [18288453.001]
  • [Cites] J Cell Physiol. 2008 Jun;215(3):665-75 [18064633.001]
  • [Cites] Oncology. 2008;75(3-4):127-33 [18791328.001]
  • [Cites] J Clin Invest. 2008 Nov;118(11):3533-6 [18982159.001]
  • [Cites] J Cell Biochem. 2008 Dec 1;105(5):1279-88 [18821572.001]
  • [Cites] Mol Cell Biol. 2009 Apr;29(7):1922-32 [19188446.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1117-23 [10666179.001]
  • (PMID = 19762145.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R21 DK075059; United States / NIAID NIH HHS / AI / R01 AI042310-06; United States / NIDDK NIH HHS / DK / DK075059; United States / NIAID NIH HHS / AI / R01 AI042310; United States / NIDDK NIH HHS / DK / DK075059-02; United States / NIDDK NIH HHS / DK / R21 DK075059-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Macrophage Migration-Inhibitory Factors; 0 / Multiprotein Complexes; 9000-94-6 / Antithrombin III
  • [Other-IDs] NLM/ NIHMS146096; NLM/ PMC2832085
  •  go-up   go-down


35. Joshi-Barve S, Amancherla K, Patil M, Bhatnagar A, Mathews S, Gobejishvili L, Cave M, McClain C, Barve S: Acrolein, a ubiquitous pollutant and lipid hydroperoxide product, inhibits antiviral activity of interferon-alpha: relevance to hepatitis C. Free Radic Biol Med; 2009 Jul 1;47(1):47-54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and can lead to hepatocellular carcinoma and end-stage liver disease.
  • This study examines the effects of acrolein on (i) IFNalpha-mediated signaling and antiviral gene expression in cultured and primary human hepatocytes and (ii) HCV replication in an HCV-replicon system.

  • Genetic Alliance. consumer health - Hepatitis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACROLEIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Nutr Food Res. 2008 Jan;52(1):7-25 [18203133.001]
  • [Cites] Chem Res Toxicol. 2007 Sep;20(9):1315-20 [17655273.001]
  • [Cites] Cell Microbiol. 2006 Jun;8(6):907-22 [16681834.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):797-801 [16682255.001]
  • [Cites] J Hepatol. 2006 Aug;45(2):271-9 [16595158.001]
  • [Cites] World J Gastroenterol. 2006 Oct 14;12(38):6098-101 [17036378.001]
  • [Cites] Ann Intern Med. 2000 Feb 15;132(4):296-305 [10681285.001]
  • [Cites] Toxicol Sci. 2000 Sep;57(1):6-15 [10966506.001]
  • [Cites] Neurobiol Aging. 2001 Mar-Apr;22(2):187-94 [11182468.001]
  • [Cites] Hepatology. 2001 Jul;34(1):121-5 [11431742.001]
  • [Cites] Chem Res Toxicol. 2002 Feb;15(2):180-6 [11849044.001]
  • [Cites] Arch Intern Med. 2002 Apr 8;162(7):811-5 [11926856.001]
  • [Cites] N Engl J Med. 2002 Sep 26;347(13):975-82 [12324553.001]
  • [Cites] Gut. 2003 Jan;52(1):126-9 [12477773.001]
  • [Cites] Mol Cell Biochem. 2002 Nov;240(1-2):83-98 [12487375.001]
  • [Cites] Liver Transpl. 2003 Apr;9(4):331-8 [12682882.001]
  • [Cites] Endocr J. 2003 Feb;50(1):61-7 [12733710.001]
  • [Cites] Cell Death Differ. 2003 Jul;10(7):772-81 [12815460.001]
  • [Cites] Free Radic Res. 2003 Jul;37(7):781-5 [12911275.001]
  • [Cites] Hepatology. 2003 Nov;38(5):1178-87 [14578856.001]
  • [Cites] Antioxid Redox Signal. 2004 Feb;6(1):19-24 [14713333.001]
  • [Cites] Ann Intern Med. 2004 Mar 16;140(6):465-79 [15023713.001]
  • [Cites] Gut. 2004 May;53(5):744-9 [15082595.001]
  • [Cites] Neurochem Int. 2004 Jun;44(7):475-86 [15209416.001]
  • [Cites] World J Gastroenterol. 2004 Oct 15;10(20):2963-6 [15378774.001]
  • [Cites] Toxicology. 2004 Nov 15;204(2-3):209-18 [15388247.001]
  • [Cites] Anal Biochem. 1987 May 15;163(1):9-15 [3619033.001]
  • [Cites] J Clin Pathol. 1997 May;50(5):401-6 [9215123.001]
  • [Cites] Free Radic Biol Med. 1998 May;24(7-8):1235-41 [9626579.001]
  • [Cites] J Hepatol. 1998 Jun;28(6):930-8 [9672166.001]
  • [Cites] Annu Rev Biochem. 1998;67:227-64 [9759489.001]
  • [Cites] J Neurochem. 1999 Feb;72(2):751-6 [9930749.001]
  • [Cites] J Hepatol. 1999 May;30(5):774-82 [10365801.001]
  • [Cites] Nature. 2005 Aug 18;436(7053):953-60 [16107835.001]
  • [Cites] Nature. 2005 Aug 18;436(7053):967-72 [16107837.001]
  • [Cites] J Allergy Clin Immunol. 2005 Oct;116(4):916-22 [16210070.001]
  • [Cites] Free Radic Biol Med. 2007 Feb 1;42(3):353-62 [17210448.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Dec;21(12):1821-5 [17074020.001]
  • [Cites] Br J Cancer. 2006 Mar 13;94(5):737-9 [16465190.001]
  • [Cites] Curr Hypertens Rep. 2007 Mar;9(1):66-72 [17362674.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2007 Jun;27(6):1319-25 [17363696.001]
  • [Cites] J Biol Chem. 2007 Jul 13;282(28):20059-63 [17502367.001]
  • [Cites] Chem Res Toxicol. 2007 Jul;20(7):986-90 [17559234.001]
  • [Cites] Minerva Gastroenterol Dietol. 2006 Jun;52(2):157-74 [16557187.001]
  • [Cites] Ann N Y Acad Sci. 2008 Apr;1126:185-9 [18448814.001]
  • (PMID = 19345260.001).
  • [ISSN] 1873-4596
  • [Journal-full-title] Free radical biology & medicine
  • [ISO-abbreviation] Free Radic. Biol. Med.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / K01 ES017105; United States / NIAAA NIH HHS / AA / R01 AA014371; United States / NIAAA NIH HHS / AA / R01 AA014371-05; United States / NIEHS NIH HHS / ES / T32 ES011564
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Air Pollutants; 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / STAT1 Transcription Factor; 0 / STAT1 protein, human; 0 / STAT2 Transcription Factor; 0 / STAT2 protein, human; 0 / peginterferon alfa-2a; 30IQX730WE / Polyethylene Glycols; 76543-88-9 / interferon alfa-2a; 7864XYD3JJ / Acrolein
  • [Other-IDs] NLM/ NIHMS123380; NLM/ PMC3947765
  •  go-up   go-down






Advertisement